Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InterCoV interferon beta-1a study in high-risk COVID-19 outpatients
PACTR202205508723236Phase 3Not yet recruiting
- Sponsor
- Medical Research Council Respiratory and Meningeal Pathogens Research Unit
- Start
- May 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of peginterferon beta-1a and interferon beta-1a in coronavirus disease 2019 (COVID-19), sponsored by Medical Research Council Respiratory and Meningeal Pathogens Research Unit. Primary endpoint: Composite clinical deterioration endpoint. Planned start May 2022; status: not yet recruiting.
02
Drugs
peginterferon beta-1ainterferon beta-1a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202205508723236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202205508723236.